Tiago M. de Carvalho

Vrije Universiteit Amsterdam — Netherlands

Medicine · Health Sciences

12h-index1.1kcitations21works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Diagnosis and Treatment(11), Prostate Cancer Treatment and Research(10), Global Cancer Incidence and Screening(8), Bladder and Urothelial Cancer Treatments(4), Cervical Cancer and HPV Research(3)

Publications21 total

Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage
International Journal of Cancer·2026Open Access
HTA185 HTA for Obesity and T2DM Indications: A Review and Recommendations for Future Appraisals
Value in Health·2025
Cost-effectiveness of risk-stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage
2025· 1 citedOpen Access
Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study
The Lancet Oncology·2022· 40 citedOpen Access
Accuracy of a smartphone application for triage of skin lesions based on machine learning algorithms
Journal of the European Academy of Dermatology and Venereology·2019· 85 cited
Development of Smartphone Apps for Skin Cancer Risk Assessment: Progress and Promise
JMIR Dermatology·2019· 56 citedOpen Access
Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators
Medical Decision Making·2019· 10 citedOpen Access
Development of Smartphone Apps for Skin Cancer Risk Assessment: Progress and Promise (Preprint)
2019· 2 cited
Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance
Cancer·2017· 11 citedOpen Access
The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials
Cancer·2017· 66 citedOpen Access
Summary statement on screening for prostate cancer in Europe
International Journal of Cancer·2017· 37 citedOpen Access
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Annals of Internal Medicine·2017· 237 citedOpen Access
Is prostate cancer different in black men? Answers from 3 natural history models
Cancer·2017· 132 citedOpen Access
When should active surveillance for prostate cancer stop if no progression is detected?
The Prostate·2017· 12 citedOpen Access
Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis
Cancer·2016· 24 citedOpen Access
Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study
British Journal of Urology·2016· 18 citedOpen Access
Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen‐detection in older (65+) men
International Journal of Cancer·2015· 6 citedOpen Access
Indirect regulation of Claudin 6 gene expression by triiodothyronine in an estrogen-positive breast cancer cell line
FEBS Journal·2015
Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data
JNCI Journal of the National Cancer Institute·2014· 160 citedOpen Access
Screening for prostate cancer in the US? Reduce the harms and keep the benefit
International Journal of Cancer·2014· 23 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Eveline A.M. Heijnsdijk(13), Harry J. de Koning(13), Monique J. Roobol(5), Vera Nelen(5), Roman Gulati(4), Jonas Hugosson(4), Anssi Auvinen(4), Maciej Kwiatkowski(4), Marco Zappa(4), Arnauld Villers(4), Angela B. Mariotto(4), Ruth Etzioni(4), Alex Tsodikov(3), Sue Moss(3), Eric J. Feuer(3), Andreea Udrea(3), Eline Noels(3), Marlies Wakkee(3), Tamar Nijsten(3), Johannes A. Bogaards(3)